跳转至内容
Merck

D-048

Supelco

N-去甲基氯氮平标准液 CRM 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H17ClN4
CAS号:
分子量:
312.80
EC 号:
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

运输

wet ice

储存温度

−20°C

SMILES字符串

Clc1ccc2Nc3ccccc3C(=Nc2c1)N4CCNCC4

InChI

1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2

InChI key

JNNOSTQEZICQQP-UHFFFAOYSA-N

一般描述

N-去甲基氯氮平是氯氮平的活性代谢物,而后者是治疗精神分裂症的非典型抗精神病药物。氯氮平在美国以Clozaril和FrazaClo®商品名出售。此款Snap-N-Spike®溶液经过认证,适用于尿液药物检测、临床毒理学、法医分析以及LC-MS/MS或GC/MS法临床监测。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

R J Flanagan et al.
Forensic science international, 206(1-3), e31-e36 (2010-08-20)
To highlight some problems that may occur when investigating clozapine-associated deaths including (i) that death may be related to gastrointestinal hypomotility and (ii) that post-mortem blood clozapine and norclozapine concentrations may not reflect ante-mortem concentrations. A 41-year-old male died 40
Tania Godoy et al.
European journal of oral sciences, 119(4), 275-281 (2011-07-06)
Many drugs (e.g. amisulpride) have been used to treat troublesome clozapine-induced salivation; however, varying success has been achieved in this respect, probably because, until recently, the salivatory action of clozapine has been largely unexplained. In the rat, clozapine and its
Thomas I F H Cremers et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(10), 1909-1916 (2012-06-28)
A significant barrier to realization of the full potential of clozapine as a therapeutic agent in the treatment of schizophrenia is the substantial interpatient variability that exists along the therapeutic continuum of no response-efficacious response-adverse response. Genetic polymorphisms that manifest
Jelveh Lameh et al.
Pharmacology & therapeutics, 115(2), 223-231 (2007-06-23)
Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated. However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy. One intriguing possibility, based on clinical correlations, receptor activity profiles and
Maria C Olianas et al.
European journal of pharmacology, 660(2-3), 341-350 (2011-04-26)
We have previously reported that N-desmethylclozapine (NDMC), a major clozapine metabolite, acts as a δ-opioid receptor agonist. Here, we show that in different cellular systems NDMC regulates protein kinase B/Akt (Akt) signaling through the activation of δ-opioid receptors. In Chinese

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门